TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications to older adults. It recommends using the Geriatrics 5Ms to assess patients’ function, nutrition and cognition, and pairing medication with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications safely and in line with older adults’ needs. The paper applies the Geriatrics 5Ms to incretin therapies, including GLP-1 medications, and calls for attention to frailty, nutrition and muscle loss before and during treatment.
The paper, titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing,” was published in the Journal of the American Geriatrics Society. Developed by the AGS Healthy Aging Special Interest Group, it uses clinical cases to show how clinicians can consider obesity medication decisions for older patients. The report says older adults are underrepresented in clinical trials, leaving clinicians with less evidence specific to this population.
The framework draws on the AGS’s 5Ms: Mind, Mobility, Medications, Multicomplexity and Matters Most. It recommends assessing functional status, nutritional adequacy and cognitive impairment before treatment. It also flags age-related concerns including sarcopenia, frailty, lean muscle loss, malnutrition and dehydration. The source does not provide a single prescribing rule or say that every older adult should receive these drugs.
The authors recommend pairing medication with supportive measures, including resistance training and adequate dietary protein. Depending on a patient’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional. The framework is described as practical guidance for clinicians, rather than a report of a new clinical trial or evidence that a particular regimen improves outcomes.
Balancing Weight Treatment With Healthy Aging
The framework addresses a clinical tension: obesity medications may offer benefits in weight management and glycemic control, but prescribing for older adults also requires attention to strength, mobility, nutrition and independence. Weight loss that coincides with loss of lean muscle or inadequate food and fluid intake could be especially consequential for someone already experiencing frailty or functional limitations. The paper highlights those risks as considerations, not as proof that the medications cause the same harms in every older patient.
For patients and clinicians, the 5Ms approach puts treatment choices into a wider picture of health. A discussion can include what the patient hopes to gain, their current function and nutrition, other medications, cognitive status and the complexity of their health needs. The recommended exercise, nutrition and team-based support also make clear that medication is not presented as a stand-alone intervention. Because older adults have been underrepresented in trials, the framework may help clinicians organize decisions while acknowledging that evidence directly applicable to this group is limited.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Levoit Core 400S-P Smart Air Purifier for Large Rooms
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms to Incretin Drugs
Incretin therapies, including GLP-1 medications, act through gut-derived hormonal pathways. The source report says these drugs have potential benefits for weight management, blood sugar control and other health conditions. It does not give medication-specific dosing instructions, compare individual drugs or specify which older adults are candidates.
The AGS framework adapts the 5Ms model of geriatric care to prescribing decisions. Rather than focusing only on a diagnosis or a target weight, it asks clinicians to consider mental and cognitive health, mobility, medications, interacting health conditions and what matters to the individual patient. The case-based format is intended to make these considerations usable in clinical practice. The report identifies the paper’s authorship and journal but does not describe a formal guideline grading process or a new trial behind the recommendations.
“Older adults are underrepresented in clinical trials.”
— The AGS framework authors, as summarized by Medical Xpress
Evidence Gaps and Patient Selection
The source report does not specify how the framework’s recommendations should change for particular ages, levels of frailty, medication doses or individual GLP-1 drugs. It also does not quantify the risks of muscle loss, malnutrition or dehydration, or report outcome data showing whether the framework improves safety or health. The extent to which trial evidence applies to older adults remains a concern because the group is described as underrepresented in clinical studies.
It is also not clear from the report whether AGS has issued a separate formal clinical guideline or how the paper’s case recommendations will be adopted in practice. The framework offers considerations for clinicians; it does not establish that obesity medication is appropriate for every older adult or replace individualized medical judgment.
How Clinicians May Use the Framework
The paper is now available in the Journal of the American Geriatrics Society for clinicians to consult. In practice, its approach points to assessment before prescribing and continued attention to a patient’s function, nutrition, cognition and goals alongside medication decisions. The report also suggests that some patients may benefit from coordination among clinicians and professionals in nutrition, physical activity and behavioral health.
The source material does not announce a future trial, implementation deadline or follow-up review. Further evidence about outcomes in older adults, and details on how clinicians apply the framework in different settings, remain open questions. Patients considering obesity medication should discuss individual risks, benefits and alternatives with a qualified health professional.
Key Questions
What did the American Geriatrics Society publish?
The AGS Healthy Aging Special Interest Group developed a case-based framework for clinicians prescribing obesity medications to older adults. It applies the Geriatrics 5Ms to incretin therapies, including GLP-1 medications.
What are the Geriatrics 5Ms?
The 5Ms are Mind, Mobility, Medications, Multicomplexity and Matters Most. The framework uses them to structure consideration of cognitive health, function, other medications, complex health needs and patient priorities.
What assessments does the framework recommend before treatment?
It calls for assessment of functional status, nutritional adequacy and cognitive impairment. It also highlights frailty, sarcopenia, possible lean muscle loss, malnutrition and dehydration as age-related considerations.
Does the paper say all older adults should take obesity medication?
No. The report describes a framework to support individualized prescribing; it does not recommend medication for every older adult or give a universal prescribing rule. Decisions should be discussed with a qualified health professional.
What support does the paper recommend alongside medication?
The authors recommend resistance training and adequate dietary protein. For some patients, care may also involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Source: medicalxpress.com
